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Objectives This study sought to compare the safety and efficacy of the Xience V/Promus everolimus-eluting stent (EES) (Ab-
bott Vascular, Temecula, California) with the Endeavor Resolute zotarolimus-eluting stent (ZES-R) (Medtronic Car-
diovascular, Santa Rosa, California) in “all-comer” cohorts.
Background Only 2 randomized controlled trials have compared these stents.
Methods The EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) and RESOLUTE-
Korea registries prospectively enrolled 3,056 patients treated with the EES and 1,998 patients treated with the
ZES-R, respectively, without exclusions. Stent-related composite outcomes (target lesion failure [TLF]) and
patient-related composite outcomes were compared in crude and propensity score-matched analyses.
Results Of 5,054 patients, 3,830 (75.8%) had off-label indication (2,217 treated with EES and 1,613 treated with ZES-R). The
stent-related outcome (82 [2.7%] vs. 58 [2.9%], p  0.662) and the patient-related outcome (225 [7.4%] vs. 153
[7.7%], p  0.702) did not differ between EES and ZES-R, respectively, at 1 year, which was corroborated by similar
results from the propensity score-matched cohort. The rate of definite or probable stent thrombosis (18 [0.6%] vs. 7
[0.4%], p  0.306) also was similar. In multivariate analysis, off-label indication was the strongest predictor of TLF
(adjusted hazard ratio: 2.882; 95% confidence interval: 1.226 to 6.779; p  0.015).
Conclusions In this robust real-world registry with unrestricted use of EES and ZES-R, both stents showed comparable
safety and efficacy at 1-year follow-up. Overall incidences of TLF and definite stent thrombosis were low,
even in the patients with off-label indication, suggesting excellent safety and efficacy of both types
of second-generation drug-eluting stents. (J Am Coll Cardiol 2013;61:536–44) © 2013 by the American
College of Cardiology Foundation
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February 5, 2013:536–44 EES Versus ZES-R in Real-World PatientsFirst-generation drug-eluting stents (DESs) substantially reduced
angiographic and clinical measures of restenosis; however,
safety issues remained (1). The most widely used second-
generation DESs, the Xience V/Promus everolimus-eluting stent
(EES) (Abbott Vascular, Temecula, California) and the
Endeavor Resolute zotarolimus-eluting stent (ZES-R)
(Medtronic Cardiovascular, Santa Rosa, California), both
made of cobalt-chromium with biocompatible polymers,
were compared in only 2 randomized controlled trials
(RCTs) (2– 4). Thus, more data about their everyday use
are needed. The purpose of this study was to evaluate the
safety and efficacy of the EES and ZES-R in everyday
real-world use with a wide range of patient and lesion
complexity.
Methods
An extended description of the study methods is presented
in the Online Appendix.
Study design and patient population. This study evalu-
ated the clinical outcomes of the EES and ZES-R from 2
prospective, multicenter registries—EXCELLENT (Effi-
cacy of Xience/Promus Versus Cypher to Reduce Late Loss
After Stenting) and RESOLUTE-Korea—that enrolled
all-comers treated with 1 EES or ZES-R (3,056/29 and
1,998/25 patients/participating centers, respectively) with-
out exclusions (Online Fig. 1). The patients enrolled in the
EXCELLENT registry were different from those enrolled
in the previously reported EXCELLENT RCT, which had
strict inclusion and exclusion criteria, the main results of
which have been published (5).
Follow-up. After index percutaneous coronary interven-
tion (PCI), follow-ups were performed at 1, 3, 9, and 12
months; angiography was optional at 9 months. For any
clinical events, all relevant medical records were reviewed
and adjudicated by an external clinical event committee.
With the use of the Korean health system’s unique
identification numbers, the vital status of 100% of pa-
tients was crosschecked. The study protocol was approved
by the ethics committee at each participating center and
conducted according to the principals of the Declaration
of Helsinki. All patients provided written informed
consent.
Definition and outcome analysis. The primary outcome
was target lesion failure (TLF), a composite of cardiac
death, myocardial infarction (MI) (not clearly attributed to
a nontarget vessel), or a clinically indicated target lesion
revascularization (TLR). The key secondary outcome, the
patient-oriented composite outcome (POCO), included
all-cause mortality, any MI (including nontarget vessel
territory), and any revascularization. Other secondary
outcomes included individual components of TLF and
POCO, and stent thrombosis (ST) defined as definite,
probable, or possible, according to the Academic Re-
search Consortium (6).Statistical analysis. First, anal-
ysis of primary and secondary
clinical outcomes was performed
in the crude population. Second,
a propensity score-matched pop-
ulation was selected to adjust for
uneven distribution of baseline
characteristics. Multivariable-
adjusted Cox proportional hazard
regression and subgroup analysis
were performed in propensity
score-matched cohorts. Probabil-
ity values were 2-sided; p 
0.05 was considered statistically
significant.
Results
Baseline characteristics. The
number of patients and lesions
were 5,054 of 7,084 for the total
cohort, 3,056 of 4,248 for the
EES group, and 1,998 of 2,836
for the ZES-R group, respec-
tively. Fifty-five (1.8%) and 32 (1.6%) patients were lost to
follow-up in the EES and ZES-R groups, respectively;
however, all were confirmed alive. The distribution of
cardiac risk factors was similar, except for dyslipidemia,
lesion complexity, and left main disease (Tables 1 and 2).
High-risk patients and lesions were frequent, implying
that our registries were an enriched population with PCI,
reflecting real-world practice in Korea. The device, le-
sion, and procedure success rates were excellent and
similar for both stents (Table 2).
Clinical outcomes of the crude population. At 1 year, the
incidence of TLF and its individual components did not
differ between the EES and ZES-R groups (2.7% vs. 2.9%,
p  0.662) (Table 3). POCO also was similar (7.4% vs.
7.7%, respectively, p  0.702), as were its individual
components. The cumulative incidence of TLF, POCO
(Fig. 1), and their individual components (Online Fig. 2)
did not differ between the 2 stents.
Stent thrombosis. Definite or probable ST occurred in
25 patients (25 of 5,054, 0.5%) without between-group
difference (Table 4, Fig. 2). When ST occurred, only 2
patients in the EES group were not taking dual antiplate-
let therapy. In the pooled analysis regarding definite or
probable ST with the RESOLUTE All Comers trial and
the TWENTE trial (3,4), the incidence of definite or
probable ST was 0.76% (37 of 4,876 patients) in the EES
group and 0.89% (34 of 3,814 patients) in the ZES-R
group, and did not differ between the 2 groups (odds ratio
[OR]: 1.00; 95% confidence interval [CI]: 0.46 to 2.19;
Abbreviations
and Acronyms
CI  confidence interval
CoCr-EES  cobalt-
chromium everolimus-
eluting stent(s)
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
POCO  patient-oriented
composite outcome
RCT  randomized
controlled trial
ST  stent thrombosis
TLF  target lesion failure
TLR  target lesion
revascularization
ZES-R  Resolute
zotarolimus-eluting stent(s)p  0.99) (Online Fig. 3).
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EES Versus ZES-R in Real-World Patients February 5, 2013:536–44Baseline Clinical Characteristics of Patients in Crude PopulationTable 1 Baseline Clinical Characteristics of Patients in Crude Population
Total
(N  5,054)
EES
(N  3,056)
ZES-R
(N  1,998) p Value
Demographics
Age (yrs) 63.9 10.8 (5,054) 63.9 10.8 (3,056) 63.9 10.9 (1,998) 0.897
Male 3,419/5,054 (67.6%) 2,053/3,056 (67.2%) 1,366/1,998 (68.4%) 0.389
BMI (kg/m2) 24.9 9.32 (4,892) 25.0 11.8 (2,935) 24.8 3.1 (1,957) 0.333
Coexisting condition
Diabetes mellitus 1,855/5,029 (36.9%) 1,149/3,031 (37.9%) 706/1,998 (35.3%) 0.068
Hypertension 3,251/5,025 (64.7%) 1,980/3,027 (65.4%) 1,271/1,998 (63.6%) 0.195
Dyslipidemia 3,268/5,017 (65.1%) 1,850/3,019 (61.3%) 1,418/1,998 (71.0%) 0.001
Peripheral artery disease 80/4,989 (1.6%) 47/2,991 (1.6%) 33/1,998 (1.7%) 0.909
Chronic renal failure 186/5,017 (3.7%) 105/3,019 (3.5%) 81/1,998 (4.1%) 0.321
Cardiac risk factors
Current smoker 1,506/4,971 (29.8%) 893/2,998 (29.8%) 613/1,973 (31.1%) 0.344
Previous PCI 757/5,035 (15.0%) 440/3,041 (14.5%) 317/1,998 (15.9%) 0.184
Previous CABG 87/5,039 (1.7%) 56/3,041 (1.8%) 31/1,998 (1.6%) 0.507
Previous MI 326/5,034 (6.5%) 212/3,036 (7.0%) 114/1,998 (5.7%) 0.079
Previous CHF 102/4,992 (2.0%) 62/2,994 (2.1%) 40/1,998 (2.0%) 0.919
Previous CVA 395/4,996 (7.9%) 250/2,998 (8.3%) 145/1,998 (7.3%) 0.181
Family history of CAD 263/4,898 (5.4%) 171/2,900 (5.9%) 92/1,998 (4.6%) 0.053
LVEF 58.8 11.4 (4,453) 59.3 11.4 (2,714) 58.0 11.4 (1,739) 0.001
LV dysfunction (LVEF 30%) 75/4,453 (1.7%) 41/2,714 (1.5%) 34/1,739 (2.0%) 0.283
Clinical Indication of PCI <0.001
Stable angina 1,696/5,036 (33.7%) 1,095/3,038 (36.0%) 601/1,998 (30.1%) 0.001
Unstable angina 1,856/5,036 (36.9%) 1,117/3,038 (36.8%) 739/1,998 (37.0%) 0.881
AMI 1,330/5,036 (26.4%) 729/3,038 (24.0%) 601/1,998 (30.1%) 0.001
NSTEMI 624/5,036 (12.4%) 344/3,038 (11.3%) 280/1,998 (14.0%) 0.005
STEMI 706/5,036 (14.0%) 385/3,038 (12.7%) 321/1,998 (16.1%) 0.001
Silent ischemia 154/5,036 (3.1%) 97/3,038 (3.2%) 57/1,998 (2.9%) 0.505
Complexity of CAD
Angiographic disease extent 0.001
1 VD 2,207/5,037 (43.8%) 1,424/3,046 (46.7%) 783/1,991 (39.3%)
2 VD 1,597/5,037 (31.7%) 923/3,046 (30.3%) 674/1,991 (33.9%)
3 VD 1,233/5,037 (24.5%) 699/3,046 (22.9%) 534/1,991 (26.8%)
No. of treated lesion/patients 1.49 0.77 (5,024) 1.47 0.74 (3,038) 1.53 0.80 (1,986) 0.009
At least 1 ISR 373/5,054 (7.4%) 231/3,056 (7.6%) 142/1,998 (7.1%) 0.548
At least 1 bifurcation 832/5,054 (16.5%) 388/3,056 (12.7%) 444/1,998 (22.2%) 0.001
At least 1 thrombotic total 561/5,054 (11.1%) 293/3,056 (9.6%) 268/1,998 (13.4%) 0.001
At least 1 small vessel* 1,033/5,054 (20.4%) 612/3,056 (20.0%) 421/1,998 (21.1%) 0.368
At least 1 long lesion† 2,215/5,054 (43.8%) 1,240/3,056 (40.6%) 975/1,998 (48.8%) 0.001
Multivessel PCI 1,569/5,054 (31.0%) 930/3,056 (30.4%) 639/1,998 (32.0%) 0.250
GP IIb/IIIa antagonist use 133/4,759 (2.8%) 61/2,763 (2.2%) 72/1,996 (3.6%) 0.004
At least 1 off-label indication‡ 3,830/5,054 (75.8%) 2,217/3,056 (72.5%) 1,613/1,998 (80.7%) 0.001
Medication at discharge
Aspirin 4,929/5,018 (98.2%) 2,969/3,030 (98.0%) 1,960/1,988 (98.6%) 0.126
Clopidogrel 4,937/5,017 (98.4%) 2,974/3,027 (98.2%) 1,963/1,990 (98.6%) 0.301
Statin 4,335/4,998 (86.7%) 2,613/3,023 (86.4%) 1,722/1,975 (87.2%) 0.468
ACE inhibitor 1,843/4,966 (37.1%) 1,113/3,011 (37.0%) 730/1,955 (37.3%) 0.810
Angiotensin-II receptor blocker 1,562/4,939 (31.6%) 939/3,016 (31.1%) 623/1,923 (32.4%) 0.363
Beta-blocker 3,159/4,970 (63.6%) 1,853/3,009 (61.6%) 1,306/1,961 (66.6%) 0.001
Calcium-channel blocker 1,343/4,931 (27.2%) 830/3,016 (27.5%) 513/1,915 (26.8%) 0.577
Values are n/N (%) or mean  SD (N). *Small vessel denotes lesion with reference diameter 2.75 mm. †Long lesion denotes lesion with length 28 mm. ‡Off-label indication: The indication of PCI was
considered “off label” if any of the following features were present: serum creatinine concentration 140 mol/l (1.6 mg/dl); LVEF 30%; an acute MI within the previous 72 h; 1 lesion per vessel; 2
essels treated with a stent; a lesion length 28 mm; or a bifurcated lesion, bypass graft, in-stent restenosis, unprotected left main coronary artery, presence of thrombus, or total occlusion.
ACE angiotensin-converting enzyme; AMI acute myocardial infarction; BMI body mass index; CABG coronary artery bypass graft; CAD coronary artery disease; CHF congestive heart failure;
CVA  cerebrovascular accident; EES  everolimus-eluting stent(s); GP  glycoprotein; ISR  in-stent restenosis; LV  left ventricle; LVEF  left ventricular ejection fraction; MI  myocardial infarction;
STEMI  non–ST-segment elevation myocardial infarction; PCI  percutaneous coronary intervention; STEMI  ST-segment elevation myocardial infarction; VD  vessel disease; ZES-R  Resolute
zotarolimus-eluting stent(s).
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February 5, 2013:536–44 EES Versus ZES-R in Real-World PatientsPropensity score-matched group analysis. Matching by
propensity score yielded 1,014 pairs with more balanced
baseline characteristics (Online Table 1, Online Fig. 4). The
cumulative incidence of TLF and POCO were comparable
between the 2 groups (log-rank p  0.675 and 0.708,
espectively) (Fig. 1), as were the individual components
nd definite or probable ST (0.6% vs. 0.2%, p  0.288)
Online Tables 2 and 3).
ndependent predictors of TLF. In multivariate analysis,
ff-label indication was the strongest predictor of TLF
adjusted HR: 2.882; 95% CI: 1.226 to 6.779; p 
.015); other significant predictors of TLF included
hronic renal failure, diabetes mellitus, and age (Table 5,
nline Table 4).
ubgroup analysis of propensity score-matched popula-
ion. Significant interaction was observed between stent
ype and multivessel PCI (pinteraction  0.032) and long
esion (pinteraction  0.016) (Fig. 3). The other subgroups
id not interact significantly with stent type and had
Baseline Angiographic Characteristics of Lesions in Crude PopulatiTable 2 Baseline Angiographic Characteristics of Lesions in Cr
Total (N  7,084)
Target vessel location
Left main artery 258/7,084 (3.6%)
LAD 3,179/7,084 (44.9%)
LCX 1,567/7,084 (22.1%)
RCA 2,071/7,084 (29.2%)
Bypass graft 9/7,084 (0.1%)
ACC/AHA lesion class
A 564/7,084 (8.0%)
B1 1,705/7,084 (24.1%)
B2 1,650/7,084 (23.3%)
C 2,285/7,084 (32.3%)
Type B2 or C lesions* 3,935/7,084 (55.5%)
In-stent restenosis 424/7,084 (6.0%)
Severe calcification 623/7,084 (8.8%)
Bifurcation† 919/7,084 (13.0%)
Bifurcation treatment 394/7,084 (5.6%)
Thrombus present 633/7,084 (8.9%)
Small vessel‡ 1,200/7,084 (16.9%)
Long lesion§ 2,671/7,084 (37.7%)
Maximum pressure deployment, atm 13.56 4.63 (6,487)
Mean stent diameter/lesion, mm 3.13 3.39 (7,084)
Total stent length, mm
Per patient 38.97 26.01 (5,054)
Per lesion 27.97 14.34 (7,084)
No. of stents
Per patient 1.67 0.97 (5,054)
Per lesion 1.19 0.49 (7,084)
IVUS-guided stenting 2,695/7,084 (38.0%)
Device success 6,908/7,084 (97.5%)
Lesion success 6,903/7,084 (97.4%)
Procedure success 6,912/7,084 (97.6%)
Values are n/N (%) or mean  SD (N). *Type B2 or C lesions according to ACC/AHA classification.
ith reference diameter 2.75 mm. §Long lesion denotes lesion with length 28 mm.
ACC  American College of Cardiology; AHA  American Heart Association; atm  atmosphere
CA  right coronary artery; other abbreviations as in Table 1.omparable rates of TLF. oiscussion
o date, this is the largest observational study comparing
ES with ZES-R. In both crude and propensity score-
atched analyses, 1-year rates of TLF and POCO were
omparable for these stents. Clinical events occurred more
ften after off-label use, the strongest predictor of TLF.
inally, the rates of ST were low in both stents considering
he complexity of the lesions treated. In contrast to previous
CTs, the rates of definite and probable ST were compa-
able between EES and ZES-R. Although well-designed
arge RCTs usually have high internal validity, their subjects
nd protocols often are not generalizable to routine practice
7). Conversely, prospective registries have the strengths of
broader patient population and reflection of routine
linical practices.
Although the patients in the EES or ZES-R group
howed several significant differences in baseline clinical and
ngiographic characteristics, which is an inherent limitation
opulation
EES (N  4,248) ZES-R (N  2,836) p Value
0.001
178/4,248 (4.2%) 80/2,836 (2.8%) 0.003
1,907/4,248 (44.9%) 1,272/2,836 (44.9%) 0.981
976/4,248 (23.0%) 591/2,836 (20.8%) 0.035
1,182/4,248 (27.8%) 889/2,836 (31.3%) 0.002
5/4,248 (0.1%) 4/2,836 (0.1%) 0.999
0.001
247/4,248 (5.8%) 317/2,836 (11.2%)
1,064/4,248 (25.0%) 641/2,836 (22.6%)
987/4,248 (23.2%) 663/2,836 (23.4%)
1,358/4,248 (32.0%) 927/2,836 (32.7%)
2,345/4,248 (55.2%) 1,590/2,836 (56.1%) 0.479
257/4,248 (6.0%) 167/2,836 (5.9%) 0.798
388/4,248 (9.1%) 235/2,836 (8.3%) 0.231
419/4,248 (9.9%) 500/2,836 (17.6%) 0.001
194/4,248 (4.6%) 200/2,836 (7.1%) 0.001
336/4,248 (7.9%) 297/2,836 (10.5%) 0.001
704/4,248 (16.6%) 496/2,836 (17.5%) 0.316
1,504/4,248 (35.4%) 1,167/2,836 (41.1%) 0.001
13.45 4.79 (3,790) 13.72 4.40 (2,697) 0.024
3.16 4.31 (4,248) 3.09 0.85 (2,836) 0.363
7.41 25.50 (3,056) 41.35 26.58 (1,998) 0.001
6.90 14.06 (4,248) 29.61 14.61 (2,836) 0.001
1.65 0.97 (3,056) 1.70 0.98 (1,998) 0.091
1.19 0.48 (4,248) 1.19 .51 (2,836) 0.467
1,601/4,248 (37.7%) 1,094/2,836 (38.6%) 0.454
4,147/4,248 (98.2%) 2,761/2,836 (98.5%) 0.484
4,145/4,248 (98.1%) 2,758/2,836 (98.5%) 0.399
4,140/4,248 (98.1%) 2,772/2,836 (98.5%) 0.479
ation means bifurcated lesion that have been treated solely by DES. ‡Small vessel denotes lesion
S  intravascular ultrasound; LAD  left anterior descending artery; LCX  left circumflex artery;onude P
3
2
†Bifurcf nonrandomized studies, these differences were balanced
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EES Versus ZES-R in Real-World Patients February 5, 2013:536–44with propensity score matching, and the clinical outcome
(both primary and all secondary) showed comparable results
between 2 stent groups.
The RCTs that previously compared these DESs
reported 1-year TLF rates (EES/ZES-R) of 8.3%/8.2%
(p  0.94) and 6.8%/7.9%, respectively (p  0.42) (2,4).
In the present study, the TLF rate was lower (2.7% vs.
2.9%, p  0.662) despite a more enriched population
with PCI in whom the rate of off-label DES use was
relatively higher (72.5% and 80.7%, respectively) than in
the RESOLUTE All Comers trial (65.6% and 67.0%,
respectively). Although 77.4% of enrolled patients had
off-label indication in the TWENTE trial, the study
excluded patients with ST-segment MI. Likewise, the
incidence of definite or probable ST also was low and
comparable (0.6% vs. 0.4%, for EES vs. ZES-R, respec-
tively). Of note, ST occurred only after off-label use.
Several trials with all-comers design and unrestricted use
of DES reported rates of definite ST, before 18 months,
ranging from 0% to 0.8% in EES (2,4,8 –11) and 0.1% to
1.2% in ZES-R (2,4,12,13). A recent meta-analysis
found significantly lower rates of definite ST in cobalt-
chromium everolimus-eluting stents (CoCr-EES) com-
pared with ZES-R at 1 year, but the rates of definite or
probable ST did not differ significantly (14). Because
most of the pooled CoCr-EES data were extracted from
the studies that did not compare CoCr-EES directly with
ZES-R, these findings should be interpreted carefully.
More direct comparisons between EES versus ZES-R
regarding ST are needed to clarify this issue.
In multivariate analysis, off-label DES use was the
strongest predictor of TLF, concordant with previous liter-
Clinical Outcomes in Crude Population at 1 YearTable 3 Clinical Outcomes in Crude Population at 1 Year
Total (N  5,054) EES (N
All-cause death 108 (2.1%) 62
Cardiac death 65 (1.3%) 37
Any MI 25 (0.5%) 17
Target vessel 19 (0.4%) 14
Nontarget vessel 6 (0.1%) 3
MI due to ST 10 (0.2%) 7
Any revascularization 267 (5.3%) 161
Clinically driven revascularization 193 (3.8%) 120
TLR 68 (1.3%) 40
Target vessel revascularization 109 (2.2%) 60
Cerebrovascular accident 30 (0.6%) 18
TLF* 140 (2.8%) 82
Target vessel failure† 182 (3.6%) 102
POCO‡ 378 (7.5%) 225
Values are n (%), unless otherwise indicated. *TLF defined as a composite of cardiac death, MI (no
at 1 year. †Target vessel failure defined as a composite of cardiac death, MI (not clearly attributed
methods at 1 year. ‡The POCOs included all-cause mortality, any MI (includes nontarget vessel ter
surgical methods).
CI confidence interval; MACEmajor adverse cardiovascular event(s); POCO patient-oriente
esion revascularization; other abbreviations as in Table 1.ature (15). Despite the extremely low TLF rates withsecond-generation DESs in this and other studies, the risk
still increases significantly, approximately 3-fold, with off-
label DES use. However, even in off-label use, the perfor-
mance of both EES and ZES-R was excellent and compa-
rable. Other independent predictors of TLF were chronic
renal failure, diabetes mellitus, and increasing age, estab-
lished risk factors after PCI (16–20).
Subgroup analysis suggested that in 2 subgroups, multi-
vessel PCI and lesions 28 mm, EES might have worse
outcomes than ZES-R. However, caution is warranted in
interpreting these results because EES 28 mm were not
available during the study period, TLF rates for ZES-R
unexpectedly decreased with increased lesion complexity,
and exploratory subgroup analysis is limited statistically by
multiple testing and small sample size.
Study limitations. This study has limitations inherent to
nonrandomized comparisons, such as allocation bias and
uneven distribution of risk factors. The stent groups
differed significantly in baseline clinical and angiographic
characteristics. These differences were balanced with
propensity score matching (Online Tables 5 to 7); how-
ever, unmeasured variables were not controlled. Second,
because data were from observational registries, detection
of events and patient follow-up were less rigorous than in
RCTs, perhaps explaining the low event rates. Even
though data were collected by dedicated study nurses,
98% patients were followed, insurance records were
reviewed, and survival status was thoroughly investigated,
nonfatal events (e.g., MI or TLR) may have been
underreported. Third, follow-up was only reported
through 1 year, too short to draw conclusions regarding
ST and safety issues. Last, systemic follow-up angiogra-
6) ZES-R (N  1,998) RR (95% CI) p Value
46 (2.3%) 1.13 (0.78–1.65) 0.551
28 (1.4%) 1.16 (0.71–1.89) 0.610
8 (0.4%) 0.72 (0.31–1.66) 0.541
5 (0.3%) 0.55 (0.20–1.51) 0.254
3 (0.2%) 2.29 (0.38–13.72) 0.686
3 (0.2%) 0.66 (0.17–2.53) 0.749
106 (5.3%) 1.00 (0.79–1.28) 0.954
73 (3.7%) 0.93 (0.70–1.24) 0.653
28 (1.4%) 1.07 (0.66–1.73) 0.803
49 (2.5%) 1.25 (0.86–1.81) 0.276
12 (0.6%) 1.02 (0.49–2.11) 0.958
58 (2.9%) 1.08 (0.78–1.51) 0.662
80 (4.0%) 1.20 (0.90–1.60) 0.217
153 (7.7%) 1.04 (0.85–1.27) 0.702
attributed to a nontarget vessel), or clinically indicated TLR by percutaneous or surgical methods
ontarget vessel), or clinically indicated target vessel revascularization by percutaneous or surgical
and any revascularization (includes all target and nontarget vessel, regardless of percutaneous or
osite outcome; RR relative risk; ST stent thrombosis; TLF target lesion failure; TLR target 3,05
(2.0%)
(1.2%)
(0.6%)
(0.5%)
(0.1%)
(0.2%)
(5.3%)
(3.9%)
(1.3%)
(2.0%)
(0.6%)
(2.7%)
(3.3%)
(7.4%)
t clearly
to a n
ritory),
d compphy was not performed, and thus mechanistic insights
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February 5, 2013:536–44 EES Versus ZES-R in Real-World PatientsStent Thrombosis in Crude Population at 1 YearTable 4 Stent Thrombosis in Crude Population at 1 Year
Total (N  5,054) EES (N  3,056) ZES-R (N  1,998) p Value
Definite 9 (0.2%) 6 (0.2%) 3 (0.2%) 0.751
Acute (0–1 day) 4 (0.1%) 3 (0.1%) 1 (0.1%) 0.657
Subacute (2–30 days) 3 (0.1%) 2 (0.1%) 1 (0.1%) 1.000
Late (31–360 days) 2 (0.1%) 1 (0.1%) 1 (0.1%) 1.000
Probable 17 (0.3%) 12 (0.4%) 5 (0.3%) 0.464
Acute (0–1 day) 4 (0.1%) 1 (0.1%) 3 (0.2%) 0.307
Subacute (2–30 days) 12 (0.2%) 10 (0.3%) 2 (0.1%) 0.142
Late (31–360 days) 1 (0.1%) 1 (0.1%) 0 (0%) 1.000
ST
Definite or probable 25 (0.5%) 18 (0.6%) 7 (0.4%) 0.306
Duration of dual antiplatelet agent
6 months 4,271/4,412 (96.8%) 2,599/2,684 (96.8%) 1,672/1,728 (96.8%) 0.930
1 yr 3,740/4,412 (84.8%) 2,277/2,684 (84.8%) 1,463/1,728 (84.7%) 0.898
Mean duration of DAT 351.09 62.62 (4,412) 351.19 62.94 (2,684) 350.94 62.15 (1,728) 0.896Figure 1 Survival Analysis: Primary and Major Secondary Outcomes
Kaplan-Meier curves are shown for each outcome and cohort combination. EES  everolimus-eluting stent(s); ZES-R  Resolute zotarolimus-eluting stent(s).Values are n (%), n/N (%), or mean  SD (N).
DAT  dual antiplatelet agent therapy; other abbreviations as in Tables 1 and 3.
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study.
Conclusions
Both stents had comparable outcomes after 1 year, with low
event rates, suggesting their excellent safety and efficacy in
real-world practice.
Figure 2 Survival Analysis: Definite or Probable ST
Arrow indicates the patients not taking dual-antiplatelet therapy at time of ST. Abb
Independent Predictors of Target LesionFailur in Propensity Sc re-Matched Group*Table 5 Ind pendent Predictors of Target LesionFailure in Propensity Score-Matched Group*
HR 95% CI p Value
Off-label indication 2.882 1.226–6.779 0.015
Chronic renal failure 2.774 1.166–6.603 0.021
Diabetes mellitus 1.957 1.128–3.396 0.043
Age 1.051 1.022–1.081 0.001
*Identification of independent predictors was done with stratified Cox proportional hazard regression
model, and the variables were presented with multivariable adjusted HRs, 95% CIs, and p values.
Variables included in the finalmodel are shown inOnline Table 7. The individual components of off-label
indication (i.e., STEMI, NSTEMI, in-stent restenosis, bifurcation, thrombotic total occlusion, long lesion,
multivessel PCI, severe left ventricular dysfunction [left ventricular ejection fraction 30%], and left
main procedure) were not included individually in the finalmodel because of significant correlationwith
off-label indication itself (i.e., collinearity between these covariates).
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.Reprint requests and correspondence: Dr. Hyo-Soo Kim, De-
partment of Internal Medicine, Cardiovascular Center, Seoul
National University Hospital, 101 Daehakro, Jongro Gu, Seoul
110-744, Republic of Korea. E-mail: hyosoo@snu.ac.kr.
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